Management of Coats’ disease with RazumabTM (World’s first biosimilar ranibizumab) and laser photocoagulation: A case report

Abstract

We report a case of a 19-year-old Indian male with stage 2 Coats' disease who was managed with monthly intravitreal biosimilar ranibizumab injections (n=3) along with laser photocoagulation in the right eye. Post-treatment, significant reductions were seen in the exudation, angioma-like lesions, central macular thickness and edema in the retina. At the last follow-up at 9 months after intravitreal biosimilar ranibizumab initiation, distant vision improved from best corrected visual acuity (BCVA) of 5/60 at baseline to 6/18, and near vision from 'not able to read' to N/12 in the right eye.

Treatment Landscape of Macular Disorders in Indian Patients with the Advent of Razumab™ (World’s First Biosimilar Ranibizumab): A Comprehensive Review

“…Razumab (0.5 mg/0.05 mL) demonstrated improved BCVA in a 50-year-old male patient who had vasculitic RVO secondary to COVID-19 [ 74 ]. In a patient with stage II Coats’ disease, Razumab treatment led to significant reductions in the exudation, angioma-like lesions, CMT and edema in the retina, and improved the distant vision (BCVA 5/60 at baseline to 6/18 post-treatment) and near vision, which was ‘not able to read’ at baseline to N/12 post-treatment [ 75 ].…”